Results 201 to 210 of about 6,008,570 (306)

Engineered Microvascular Model of the Blood–Brain–Tumor Barrier Reveals Endothelial Remodeling in Diffuse Midline Glioma

Advanced Healthcare Materials, EarlyView.
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett, Yann S. Vanrobaeys, Tessy Teboh, Zakiya Smith, Anderson Scott, Cynthia Hajal, Paula T. Hammond, Joelle P. Straehla   +7 more
wiley   +1 more source

<i>SYNE1</i> Deficiency Manifesting Primarily With Motor Neuron Disease. [PDF]

Neurol Genet
Senghor HVF, Rubio RD, Marco C, Salazar-Villacorta A, Padró-Miquel A, Beltran S, Matalonga L, Márquez F, Sy HA, Sy M, Povedano M, Diop AG, Ndiaye M, Rodríguez Cruz PM.   +13 more
europepmc   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

Age-period-cohort effect on motor neuron disease mortality in the United States, 2001-2020. [PDF]

Front Neurol
Raymond J, Larson T, Nair T, Kaufman J, Horton DK, Weisskopf M, Mohidul S, Mehta P.   +7 more
europepmc   +1 more source

Familial motor neurone disease [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1964
openaire   +2 more sources

How is Nanoarchitectonics Shaping Extracellular Vesicle Research?

Advanced Healthcare Materials, EarlyView.
The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake, Md Shahriar A. Hossain, Chia‐Hung Liu, Carlos Salomon, Yusuke Yamauchi, Mostafa Kamal Masud   +5 more
wiley   +1 more source

Analysis and comparison of the trends in the burden of motor neuron disease in China and worldwide from 1990 to 2021. [PDF]

PLoS One
Fu Y, Wei Y, Pang Z, Yang J, Sun X.
europepmc   +1 more source

Multiwavelength Implantable Oximeter for Wireless Monitoring of Tissue Oxygenation in the Presence of Blood Volume Changes

Advanced Healthcare Materials, EarlyView.
This study presents an implantable, wireless, battery‐free oximeter that can continuously monitor physiologically consistent regional tissue oxygenation under dynamic changes of blood volume. This is achieved through multiwavelength photoplethysmography and validated both via Monte Carlo simulations and in vivo rat studies. Different stress events were
Anat Usatinsky, Hugo L. Higueros‐Garcia, Sadi Loai, Samantha Unger, Jacob Trueb, Yonatan Usatinsky, Rawad Alkallas‐Valdiviezo, Noor Abu Jarad, Jonathan Wu, Hai‐Ling M. Cheng, John A. Rogers, Abraham Vázquez‐Guardado, Daniel Franklin   +12 more
wiley   +1 more source

Synaptic and cytoskeletal CSF signatures of motor neuron disease: the role of cyclase-associated protein 2. [PDF]

Sci Rep
Pilotto A, Pelucchi S, Trasciatti C, Ferullo L, Poli L, Tolassi C, Catanese A, Girotto I, Labella B, Gorla F, D'Andrea L, Stringhi R, Di Luca M, Marcello E, Padovani A.   +14 more
europepmc   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

Advanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans, Abdulwahhab Khedr, Panagiotis G. Georgiou, Nehir Arik, Ozlem Sen, Steve P. Rannard, Tom O. McDonald, Christos Tapeinos   +7 more
wiley   +1 more source